相似文献
1
ATG in allogeneic stem cell transplantation: standard of care in 2017? Counterpoint.
Blood Adv. 2017 Mar 28;1(9):573-576. doi: 10.1182/bloodadvances.2016001552.
2
ATG in allogeneic stem cell transplantation: standard of care in 2017? Point.
Blood Adv. 2017 Mar 28;1(9):569-572. doi: 10.1182/bloodadvances.2016001560.
3
Related haploidentical donors are a better choice than matched unrelated donors: Counterpoint.
Blood Adv. 2017 Feb 14;1(6):401-406. doi: 10.1182/bloodadvances.2016002188.
4
Related haploidentical donors are a better choice than matched unrelated donors: Point.
Blood Adv. 2017 Feb 14;1(6):397-400. doi: 10.1182/bloodadvances.2016002196.
5
Antifibrinolytic therapy for preventing VWD-related postpartum hemorrhage: indications and limitations.
Blood Adv. 2017 Apr 25;1(11):699-702. doi: 10.1182/bloodadvances.2017005082.
6
Should minimal residual disease negativity be the end point of myeloma therapy?
Blood Adv. 2017 Mar 14;1(8):517-521. doi: 10.1182/bloodadvances.2016000117.
7
Platelets and hemostasis: a new perspective on an old subject.
Blood Adv. 2016 Nov 22;1(1):5-9. doi: 10.1182/bloodadvances.2016000059. eCollection 2016 Nov 29.
8
Platelets as immune-sensing cells.
Blood Adv. 2016 Nov 22;1(1):10-14. doi: 10.1182/bloodadvances.2016000067. eCollection 2016 Nov 29.
9
Should minimal residual disease negativity be the end point of myeloma therapy?
Blood Adv. 2017 Mar 14;1(8):522-525. doi: 10.1182/bloodadvances.2017000109.
10
Immunotherapy in adult acute lymphoblastic leukemia: the role of monoclonal antibodies.
Blood Adv. 2016 Dec 27;1(3):260-264. doi: 10.1182/bloodadvances.2016000042.
引用本文的文献
1
Optimizing anti-thymocyte globulin dosing in allogeneic hematopoietic stem cell transplantation: individualized approaches and clinical implications.
Front Immunol. 2025 Aug 8;16:1634157. doi: 10.3389/fimmu.2025.1634157. eCollection 2025.
2
The delicate balance of graft versus leukemia and graft versus host disease after allogeneic hematopoietic stem cell transplantation.
Expert Rev Hematol. 2023 Jul-Dec;16(12):943-962. doi: 10.1080/17474086.2023.2273847. Epub 2023 Dec 18.
3
Immunopathogenic mechanisms and modulatory approaches to graft-versus-host disease prevention in acute myeloid leukaemia.
Best Pract Res Clin Haematol. 2023 Jun;36(2):101475. doi: 10.1016/j.beha.2023.101475. Epub 2023 May 11.
4
Addition of ATG to non-myeloablative peripheral blood haploidentical transplant with PTCY decreases acute GVHD rates and improves GVHD-relapse free survival.
Bone Marrow Transplant. 2023 Jun;58(6):723-726. doi: 10.1038/s41409-023-01956-y. Epub 2023 Mar 23.
5
Different effects of thymoglobulin on acute leukemia with pre-transplant residual blasts in HLA mismatch transplantation.
Int J Hematol. 2023 Jun;117(6):889-899. doi: 10.1007/s12185-023-03563-5. Epub 2023 Feb 22.
6
Neurological complications following pediatric allogeneic hematopoietic stem cell transplantation: Risk factors and outcome.
Front Pediatr. 2022 Dec 2;10:1064038. doi: 10.3389/fped.2022.1064038. eCollection 2022.
7
A phase II, prospective, randomized, open-label study of defibrotide added to standard-of-care prophylaxis for the prevention of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Haematologica. 2023 Apr 1;108(4):1026-1038. doi: 10.3324/haematol.2022.281471.
8
Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience.
Ann Hematol. 2021 Jul;100(7):1837-1847. doi: 10.1007/s00277-021-04521-z. Epub 2021 May 4.
9
Factors Associated with Post-Transplant Active Epstein-Barr Virus Infection and Lymphoproliferative Disease in Hematopoietic Stem Cell Transplant Recipients: A Systematic Review and Meta-Analysis.
Vaccines (Basel). 2021 Mar 19;9(3):288. doi: 10.3390/vaccines9030288.
10
Incorporation of posttransplant cyclophosphamide as part of standard immunoprophylaxis for all allogeneic transplants: a retrospective, single institution study.
Bone Marrow Transplant. 2021 May;56(5):1099-1105. doi: 10.1038/s41409-020-01144-2. Epub 2020 Dec 1.
本文引用的文献
1
Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.
J Clin Oncol. 2017 Dec 20;35(36):4003-4011. doi: 10.1200/JCO.2017.75.8177. Epub 2017 Oct 17.
2
Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation.
Blood. 2016 Dec 8;128(23):2734-2741. doi: 10.1182/blood-2016-06-721936. Epub 2016 Oct 4.
3
Individualized conditioning regimes in cord blood transplantation: Towards improved and predictable safety and efficacy.
Expert Opin Biol Ther. 2016 Jun;16(6):801-13. doi: 10.1517/14712598.2016.1164688. Epub 2016 Mar 28.
4
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.
N Engl J Med. 2016 Jan 7;374(1):43-53. doi: 10.1056/NEJMoa1506002.
5
Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial.
Lancet Oncol. 2016 Feb;17(2):164-173. doi: 10.1016/S1470-2045(15)00462-3. Epub 2015 Dec 24.
6
Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis.
Lancet Haematol. 2015 May;2(5):e194-203. doi: 10.1016/S2352-3026(15)00045-9. Epub 2015 Apr 21.
7
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.
Blood. 2015 Aug 20;126(8):1033-40. doi: 10.1182/blood-2015-04-639831. Epub 2015 Jun 30.
8
Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning.
J Clin Oncol. 2014 Nov 1;32(31):3497-505. doi: 10.1200/JCO.2013.54.0625. Epub 2014 Sep 29.
9
Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation.
Blood. 2014 Jun 5;123(23):3664-71. doi: 10.1182/blood-2014-01-552984. Epub 2014 Apr 17.
10
Rabbit anti-T-lymphocyte globulin (ATG) persists with differential reactivity in patients' sera after full hematopoetic regeneration from allogeneic stem cell transplantation.
Transpl Immunol. 2014 May;30(4):136-9. doi: 10.1016/j.trim.2014.03.005. Epub 2014 Apr 13.
Zotero 插件